Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
5/24/2026, 12:00:00 AM
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
Korean Translation
2026년 5월 24일 레켐비(LEQEMBI) 피하주사 제형의 보충적 생물의약품 허가신청(sBLA)에 대한 FDA PDUFA 목표일이 예정됨. 시장 반응 불확실로 중요도는 추정치이며 예정됨.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release is scheduled. High importance estimated due to expected market volatility.
5/13/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Analysts forecast EPS of approximately $0.62 forecasted. Q1 2026 earnings release scheduled. Low impact expected for routine announcement.
5/6/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q1 2026 earnings release is scheduled for May 5, 2026, with analysts forecasting EPS of approximately $1.27, estimated. Medium importance is estimated as earnings reports typically drive significant price volatility, scheduled.
5/5/2026, 12:00:00 AM
Palantir Technologies Inc (PLTR) · Earnings Release
Palantir's Q1 2026 earnings release, for which low importance is estimated as the market typically reacts to the actual data rather than the schedule, is scheduled.
5/4/2026, 12:00:00 AM